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A recombinant (r) NH2-terminal fragment of bactericidal/permeability-increasing protein,
rBPI 23 , was shown to inhibit murine macrophage nitric oxide (NO) production elicited by lipo-
polysaccharide (LPS) plus interferon-v (IFN-'Y). Normal mouse plasma amplified NO synthesis
(measured as N02 release) at LPS concentrations of 1-10 ng/rnl., and antibody to the plasma
LPS-binding protein (LBP) partially inhibited N02 release in the presence of normal mouse
plasma. rBPI 23 (1 Ilg/mL) effectively inhibited LPS-dependent N02 release in the presence or
absence of normal mouse plasma. Fifty percent inhibition of IFN-'Y/LPS-elicited N02 produc-
tion or of binding of fluoresceinated LPS was obtained with --0.2 Ilg/mL rBPI 23 • These results
provide a basis for studies of rBPI23 effects on NO synthase activity in murine models of gram-
negative sepsis.
Lipopolysaccharide (LPS), either as part of the outer mem-
brane of gram-negative bacteria or when released into the
circulation upon bacterial lysis. is a potent stimulus ofmacro-
phage cytokine production and mediator release [I, 2]. De-
spite extensive investigation, the precise mechanism(s) by
which LPS stimulates macrophage function is still unknown.
Recently, a plasma protein, LPS-binding protein (LBP), was
shown to bind to smooth and rough LPS [3-5]. Macrophage
cell surface protein CD 14 was subsequently shown to recog-
nize the LBP-LPS complex [6], and several studies have now
demonstrated dramatic enhancement of both binding ofand
functional responses to LPS by purified LBP [6-11]. Further-
more, transfection of cDNA encoding CD 14 into a murine
pre-B lymphocyte cell line, which does not normally express
this gene, strongly increased the sensitivity of those cells to
low concentrations of LPS in the presence of LBP [12]. Al-
though such results do not imply that CD 14 alone can initi-
ate signal transduction, they provide evidence for an impor-
tant role of LBP in modifying host responses to LPS.
Another LPS-binding protein, the neutrophil granule bac-
tericidal/permeability-increasing protein (BPI), binds to LPS
in the outer membrane of gram-negative bacteria, causing
permeability and cell death [13-16]. Although BPI shows
striking sequence homology to LBP [7, 17], the two proteins
exert different effects on LPS activity. BPI, its Nl-l--tcrminal
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fragment, and recombinant (r) BPI inhibit LPS activity in
various in vitro systems, including activation oflimulus ame-
bocyte lysate [18]. priming for neutrophilleukotriene release
[18] or LPS-elicited complement receptor expression [19],
and induction of tumor necrosis factor (TNF) secretion by
human monocytes [18, 20]. Recently, a recombinant pro-
tein, rBPI23 , corresponding to the amino-terminal region of
human BPI was produced and purified [21]. rBPI23 showed
high affinity binding to lipid A and various types of LPS and
LPS-neutralizing activity [16, 22]. We have recently demon-
strated that rBPI23 inhibits the plasma-mediated binding of
LPS to human monocytes in a dose-dependent manner [23].
Moreover, antibody to murine LBP inhibited LPS binding in
normal mouse plasma (NMP) [11, 23], suggesting that bind-
ing occurs through the CD 14/LBP pathway and that rBPI23
must compete with LBP to be an efficient inhibitor of LPS.
Although certain macrophage responses such as TNFa se-
cretion occur with LPS alone. other activities. including the
induction ofcytotoxic activity toward tumor cells or intracel-
lular pathogens and synthesis of nitric oxide (NO), are
greatly enhanced by costimulation of LPS with interferon-v
(IFN-'Y) [24-27]. NO and its stable derivatives NO;- and
NO;- are derived from L-arginine via the action ofa group of
enzymes termed NO synthases [28. 29]. The constitutive
isoenzyme present in endothelial and neuronal cells is rever-
sibly regulated by free calcium ions and can rapidly generate
small amounts of NO. Moreover. a cytokine-inducible NO
synthase, most extensively studied in murine macrophages,
is a calcium-independent enzyme capable of producing
much higher levels ofNO over a prolonged period. Although
constitutive production ofNO is believed to playa role in the
maintenance of vascular tone, increased production or indis-
criminate release occurring on activation of inducible NO
synthase could contribute to the hypotension observed dur-
ing septic shock [28. 30].
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We recently reported that purified rabbit LBP significantly
enhanced NO production by murine bone marrow-derived
macrophages stimulated with LPS plus IFN-')' [9]. We have
now examined the effects of rBPI z3on NO production (mea-
sured as N02) using a homologous system in which murine
macrophages were stimulated in the presence of NMP as a
source of LBP and other plasma factors that might modulate
LPS function.
Materials and Methods
Animals. CBA female mice were obtained from IFFA-
CREDO (Saint Germain-sur-l'Arbresle, France) and used at
5-10 weeks of age.
Reagents. A recombinant Nllj-terminai fragment of BPI
(rBPI z3) was obtained from XOMA (Berkeley, CA). rIFN-')' (lot
no. 2309-24, produced by Genentech, South San Francisco)
was supplied by Boehringer Ingelheim (Vienna). Polymyxin B,
phenol-extracted LPS, and fluorescein-labeled LPS (FITC-LPS)
from Escherichia coli 0 I I I were purchased from Sigma (St.
Louis). Recombinant human TNFa was a gift from BASFj
Knoll (Ludwigshafen, Germany). Polyclonal antibody to puri-
fied murine LBP was raised in rabbits and purified by protein A
affinity chromatography as previously described [II]. High-ti-
tered rabbit polyclonal antibody to E. coli 0 III LPS was ob-
tained by intravenous injection of heat-killed stationary phase
bacteria (5 X 109 three times weekly for 2 weeks). Pooled heat-
inactivated (56°C, 30 min) serum was stored at -20°C until
use. Preimmune normal rabbit serum and purified IgG served as
control antibodies.
Macrophage cultures. Macrophages were obtained by in vi-
tro differentiation of bone marrow precursor cells [31]. Day 10
or I I macrophages were detached by pipetting, suspended in
Dulbecco's MEM (DMEM; Seromed, Munich) supplemented
with 10% fetal calf serum (FCS; Seromed), and distributed in
96-well microculture plates (75,000jwell).
Infection of macrophage cultures. Macrophages were in-
fected with Leishmania enriettii promastigotes as previously de-
scribed [32] at a parasite-to-macrophage ratio of 16: I.
Macrophage activation. Infected or noninfected macro-
phages were washed with Hanks' balanced salt solution to re-
move serum and then cultured overnight with IFN-')' plus LPS
or TNFa in the presence or absence of rBPIz3 or I%pooled NMP
or both. Alternatively, macrophages were primed with 10 units/
mL IFN--y for 24 h prior to stimulation with LPS (with or with-
out rBPI23) for an additional 24 h.
TNF assay. Secretion of TNF was determined by biologic
assay of supernatants collected 4 h after addition of LPS [33].
WEHI 164 clone 13 cells in 10%FCS-supplemented RPMI me-
dium (10,000 cellsj90 JlL) were added to microtiter wells con-
taining 90 JlL of serial dilutions of test supernatant or standard
rTNFa. Plates were incubated at 3rC for 48 h; 20 JlL of 3-( 1,4
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT;
United States Biochemicals, Cleveland; 5 rng/ml. in RPMI me-
dium) was then added. After 4 h at 37°C, supernatants were
removed, and reduced dye was solubilized with 0.2 mL of 20
mM HCI in isopropanol containing 3%SDS. Optical density was
Table 1. Inhibition of lipopolysaccharide (LPS)-elicited tumor
necrosis factor-a (TNFa) production by recombinant (r) BPIz3•
TNF units/rnl,
LPS (ng/ml.) Control BPI PB
3 2 0* 0
10 8 0 0
30 20 5 0
500 12 10 5
NOTE. BPI23 or polymyxin B (PB), I ~g/mL. 50% inhibition was ob-
tained with 0.08 units/rnl, TNFa. Results are average ofduplicate superna-
tants and represent 4 independent experiments.
* Undetectable in 1:5 dilutions of macrophage supernatant «0.4 units/
mL).
determined at 570 nm using a microELISA reader fitted with a
620-nm reference filter. Preliminary experiments demonstrated
that rBPl z3 at the concentrations added to macrophage cultures
had no effect on WEHI target cell viability either in the presence
or absence of TNFa (data not shown).
NO] release. Twenty-four-hour macrophage supernatants
( 100 JlL) were assayed for N02by the Griess reaction according
to a recently described microassay [34]. Briefly, an equal volume
of Griess reagent (I % sulphanilamidejO.1 % naphthylethylene-
diamine dihydrochloridej2.5% H3P04 ) was incubated with mac-
rophage supernatants for 10 min at room temperature, and ab-
sorbance was measured at 550 nm in a microELISA reader using
a 620-nm reference filter. N02 concentration (nrnol/well) was
determined using NaNOz as a standard. The SE of replicate de-
terminations was < 10%.
Measurement of intracellular parasite killing. After a 24-h
incubation in the presence or absence ofvarious activators, mac-
rophages were lysed by exposure to 0.0 I% SDS as described
[32]. The wells were then supplemented with DMEM plus FCS
and hemin, and parasite growth was recorded by measuring [3H]_
thymidine incorporation [32].
Fluorescence-activated cell. sorting analysis of LPS binding.
Bindi.ng of fluoresceinated LPS was determined as previously
descnbed [8]. Macrophages (I 06jmL of RPMI containing 4%
bovine serum albumin and 1% NMP) were incubated with 10 or
100 ng ofFITC-LPS in the presence or absence ofrBPIz3 for 60
min at 37°C. Cells were then washed twice with cold PBS and
resuspended in RPMI (10 6jmL). Macrophage fluorescence was
analyzed using FACScan (Becton Dickinson, Mountain View,
CA) flow cytometry.
Results
Inhibition of LPS-elicited TNF production by rBPI .
. 23
Previous studies showed that purified or recombinant BPI
inhibits LPS-elicited TNF production by human peripheral
blood mononuclear cells or whole blood cultures [18, 20].
We therefore examined the ability of rBPI z3 to inhibit TNF
production by the murine bone marrow-derived cultures to
be used in studies of NO induction. As shown in table I, I
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"'( for 24 h, extensively washed, and then stimulated with LPS
in the presence of 1% NMP with or without rBPI23 • Half-
maximal inhibition was obtained with 0.1-0.3 J,Lg/mL rBPI23
and nearly complete inhibition with 0.5 J,Lg/mL. With a 10-
fold higher concentration of LPS (100 ng/ml.), I J,Lg/mL
rBPI23 still inhibited N02' production by >50% (not shown).
Inhibition of NO] production by antibody to LBP. The
ability of rBPI23 to inhibit macrophage activation by LPS
may depend in part upon its capacity to compete with
plasma LBP. NMP contains -2 Jlg/mL LBP as determined
Figure 1. Dose-dependent inhibition by recombinant (r) BPI23
of lipopolysaccharide (LPS)-elicited nitrite (N02") production. In-
terferon-v-primed macrophages were washed and stimulated with
I. 3, or 10 ng/rnl, LPS and I%normal mouse plasma immediately
after addition ofvarious concentrations ofrBPI23 • Each point repre-
sents %inhibition ofcontrol N02" release in absence ofrBPI23 calcu-
lated as mean ofthree determinations. Data are from three indepen-
dent experiments (0. • , ~). Absolute nrnol/well N02" release in
control cultures (mean of three experiments ± SE): I ng/ml, LPS,
1.0 ± 0.1; 3 ng/ml, LPS, 2.0 ± 0.2; 10 ng/rnl, LPS, 4.0 ± 0.7.
I%NMP
IFN--y
3 units/rnl, + LPS. 10 ng/mL 3.3 0.7
100 units/ml, +
LPS. I ng/rnl, 5.9 0.4
TNFa. 1000units/rnl, 2.1 2.0
NoNMP
IFN--y
3 units/ml, + LPS, 10 ng/mL 0.6 0
100 units/rnl, +
LPS, I ng/ml, 0.4 0
TNFa, 1000 units/ml, 2.0 1.9
N02- (nrnol/well)
Table 2. Inhibition of macrophage N02" production by recombi-
nant (r) BPI23 is specific for lipopolysaccharide (LPS)-induced acti-
vation.
NOTE. rBPI23 , I Ilg/mL. Nitrite (N02') represents mean of triplicate
wells (SE, :;:;;0.1 nrnol/well). Interferon-v (lFN--y) alone. <0.1 nmol of
N02'/well. Data are from a typical experiment and represent 4 independent
experiments. NMP. normal mouse plasma: TNFa. tumor necrosis factor-a.
Alone Plus rBPI23
J,Lg/mL rBPI23 effectively inhibited TNF secretion induced by
3 or 10 ng/rnl, LPS in the presence of 1% NMP. This inhibi-
tion was overcome at higher LPS concentrations. LPS activ-
ity was also inhibited by polymyxin B at I J,Lg/mL. TNF was
undetectable in control untreated cultures (not shown).
Inhibition of nitrite production in response to IFN-"'( and
LPS. We then determined if rBPI23 could inhibit NO syn-
thesis (measured as N02') by murine macrophages under
conditions similar to those described above for TNF produc-
tion. Since LPS alone is a relatively poor stimulus for N02'
production, macrophages were cultured with LPS plus IFN-"'(
as a priming signal. N02' release elicited by IFN-"'( plus LPS
was much higher in the presence of 1% NMP than in the
plasma-free cultures (table 2). Increasing the concentration
of NMP did not further promote N02' production under
these conditions (data not shown). Addition of I J,Lg/mL
rBPI23 effectively inhibited N02' production in the presence
or absence of plasma. To ensure that the inhibitory effect of
rBPI23 was specific, macrophages were alternatively stimu-
lated with IFN-"'( plus TNFa. N02' release elicited by IFN-"'(
plus TNFa was independent of the presence of plasma and
was not inhibited by rBPI23 (table 2). These results demon-
strate that rBPI23 did not exert nonspecific toxicity or inhibi-
tory effects on murine bone marrow-derived macrophages
resulting in failure to induce NO synthetic capacity. More-
over, no differences were seen in the amount of cell-asso-
ciated protein in each well at the end of the incubation (not
shown), further evidence that rBPI23 was not toxic for these
cultures.
Figure I presents the dose-dependency of the rBPI23 effect.
For these experiments, macrophages were primed with IFN-
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NOTE. Binding in 4% albumin (negative control) was 2.5-2.6 fluores-
cence units.
Table 4. Recombinant (r) BPl23 inhibition of lipopolysaccharide
(LPS) binding by primed or unprimed murine macrophages.
014 8
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Figure .2. Inhibition of macrophage nitrite (N02") production by
recombinant (r)BPI 23 added at various times after lipopolysaccha-
ride (LPS) exposure. rBPl23 (I JLg/mL)was added to primed macro-
phages at various times relative to addition ofLPS at I (e), 3 (A), or
10 ng/ml. (0). Data are %inhibition ofN02" production; each point
represents mean ± SE of at least three independent experiments.
Absolute nrnol/well N02"release in control cultures (mean of3 or 4
experiments ± SE): I ng/ml, LPS, 0.7 ± 0.1; 3 ng/mL LPS, 2.2 ±
0.3; 10 ng/rnl, LPS, 3.2 ± 0.2.
phase rabbit serum enhanced the binding of I JLg/mL FITC-
LPS to bone marrow-derived macrophages [9]. Further-
more, anti-LBP inhibited LPS binding in the presence of
rabbit or murine sera [9, II]. Since N02" production is in-
duced by much lower levels of LPS than those used in the
binding experiments, we have now examined the binding of
10 or 100 ng/rnl. FITC-LPS to bone marrow-derived macro-
phages using 1% NMP. In addition, primed and unprimed
macrophages were compared since both populations were
used to study the effects of rBPI23 on NO production, and it
was possible that IFN-')' pretreatment might modify the ex-
pression ofmacrophage CD 14 or other putative LPS receptor
molecules. As shown in table 4, 1 JLg/mL rBPI23 strongly
inhibited binding at either LPS concentration. Furthermore,
virtually no differences were detectable between the primed
and unprimed populations. Inasmuch as low but reproduc-
ible binding of 10 ng/mL LPS was detectable in these experi-
Macrophage status.
LPS concentration (ng/rnl.)
Unprimed
10
100
Primed
10
100
% inhibition ofNO;- production
LPS I LPS 3 LPS 10 TNFa
Anti-LPS 100 NO 89 7
NO 100 87 0
100 97 83 0
Anti-LBP 88 27 NO 0
79 32 NO 0
Table 3. Inhibition of lipopolysaccharide (LPS)-dependent N02"
production by anti-LPS-binding protein (LBP) and anti-LPS.
by RIA (unpublished data). The recent availability of puri-
fied polyclonal antibody directed against murine LBP [II]
allowed us to examine its effect on N02" production stimu-
lated by LPS in the presence of 1% NMP using IFN--y-
primed macrophages.
Macrophages were alternatively stimulated with TNFa
plus IFN--y, and rabbit polyclonal antiserum directed against
E. coli 0111 LPS was used as a positive control for inhibition
of LPS-dependent stimulation. Anti-LPS (three experi-
ments) inhibited N02" production elicited by LPS but not by
IFN--y/TNFa (table 3). In two experiments, anti-LBP simi-
larly inhibited only LPS-induced N02" release. No inhibition
was observed with normal rabbit serum or purified preirn-
mune rabbit IgG (data not shown). These results are consis-
tent with the NMP-dependent enhancement of N02" release
as well as with results from a previous study [9], demonstrat-
ing that purified rabbit LBP enhances N02" production by
LPS-stimulated murine macrophages.
Inhibition ofLPS-mediated NO] production as afunction of
time of rBP/n addition. The effect of time of rBPI23 addi-
tion on its inhibition of NO production was examined using
IFN--y-primed macrophages. rBPI23 strongly inhibited N02"
release when added up to I h after I or 3 ng/rnl, LPS plus 1%
NMP (figure 2). Moreover, rBPI23 consistently inhibited the
response to I ng/ml, LPS even when added as late as 4 h.
Induction of NO synthesis appeared to be an even slower
process in the absence ofplasma since inhibition of 3 ng/rnl,
LPS was obtained when rBPI23 was added 8 h after LPS (data
not shown). When the concentration ofLPS was increased to
10 ng/mL (I % NMP), rBPI23 did not inhibit N02" release
when added 30 min after stimulation (figure 2). We there-
fore examined the effects of delaying the addition of inhibi-
tor for shorter periods. In three experiments, addition of
rBPI23 10 min after 10 ng/ml, LPS inhibited N02" release by
40.7% ± 4.2% (mean ± SE).
Inhibition of LPS binding to murine macrophages by
rBP/n . We previously reported that purified LBP or acute-
NOTE. LPS. 1-10 ng/ml.; tumor necrosis factor-a (TNFa). 1000 units/
mL in the presence of 100 units/rnl, interferon-v (IFN-'Y); anti-LPS (I :500
dilution). anti-LBP (400 JLg IgG/mL). Absolute nrnol/well nitrite (NO;-) in
control cultures (mean ± SE): LPS I. 0.7 ± 0.1: LPS 3. 2.1 ± 0.2; LPS 10.
3.8 ± 0.1; IFN-'Y/TNFa. 1.9 ± 0.3. NO. not determined.
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Figure 3. Dose-dependent inhibition of lipopolysaccharide
(LPS) binding to murine macrophages by recombinant (r)BPI23 •
Interferon-v-prirned macrophages (10 units/ml., 24 h) were incu-
bated with 10 ng/mL fluorescein isothiocyanate-LPS (FITC-LPS)
and I% normal mouse plasma with or without increasing concen-
trations of rBPI 23 for I h at 37°C. LPS binding measured as FITC-
LPS fluorescence is presented as %ofcontrol binding in absence of
rBPI 23 • Mean fluorescence (arbitrary units) of 10,000 cells in con-
trol: experiment (exp) I (0), 4.8; exp II (~), 4.7.
ments, we could directly compare the capacity of rBPI23 to
inhibit binding with its effect on NO zrelease. When binding
of 10 ng/rnl, FITC-LPS was examined in the presence of 1%
NMP (figure 3), half-maximal inhibition ofmacrophage fluo-
rescence was obtained with --0.2 JLgjmL rBPI23 (i.e., con-
centrations similar to those for NOzproduction). To further
examine the relationship between LPS binding and NO pro-
duction, rBPI23 was added 10 min after 10 ngjmL FITC-LPS.
In three experiments, delaying the addition of rBPI23 de-
creased the inhibition of macrophage fluorescence from
95.3% ± 3.8% (rBPI23 at time 0) to 29.0% ± 4.4% (rBPI 23 at
10 min).
Inhibition of intracellular leishmanicidal activity. Since
rBPI23 could inhibit the induction of NOzrelease, it was of
interest to examine its effects on an in vitro system in which
NO is known to have biologic activity. An excellent correla-
tion exists between murine macrophage activation for NO
production and the ability to kill intracellular Leishmania
species [35-37]. We therefore examined the effects ofrBPI23
on leishmanicidal activity stimulated by LPS. Macrophages
infected with Leishmania species 24 h before stimulation gen-
erally produce higher levels of NOzthan do uninfected cells
(unpublished data). Addition of IFN-')' plus LPS or IFN-')'
plus TNFa induced NOzsecretion and leishmanicidal activ-
ity (table 5). In cultures stimulated with IFN-')' and LPS, BPI
inhibited NOzproduction and abolished intracellular kill-
ing. rBPI23 did not inhibit cytotoxic activity nonspecifically
since intracellular killing induced by IFN-')' plus TNFa was
unaffected by rBPI23 • Furthermore, the ability of control
macrophages (DMEM or IFN-')' alone) to support Leish-
Discussion
mania infection in the presence of rBPI23 is further evidence
for the lack of toxicity of this molecule under the in vitro
conditions used in this study.
Production ofa large array of cytokines and inflammatory
mediators by LPS-activated macrophages undoubtedly con-
tributes to the pathologic manifestations of gram-negative
sepsis. In particular, current evidence suggests that rapid re-
lease of TNFa in response to picogram concentrations of
LPS is responsible for many of the clinical symptoms asso-
ciated with lethal endotoxemia [38]. However, high levels of
serum TNF are not necessarily associated with mortality
[39]. Circulating levels of IFN-')' are also detectable in pa-
tients and in experimental models of endotoxic shock and,
recently, we [40] and others [41,42] have demonstrated that
monoclonal antibodies to IFN-')' can significantly decrease
lethality in vivo.
As previously shown for macrophage cytolytic activity, ef-
ficient induction of NO production by either LPS or TNFa
requires costimulation by IFN-')' [26, 34]. Although it has
been suggested that induction of the Ca2+-independent NO
synthase pathway is important in the pathogenesis of endo-
toxic shock, recent attempts to correlate toxicity of bacterial
products with enzyme induction in vivo have been unsuc-
cessful [43, 44]. Since in vivo models designed to test the
Table 5. Recombinant (r) BPI23 inhibits intracellular leishmani-
cidal activity of bone marrow-derived macrophages stimulated by
interferon (IFN)-')' plus lipopolysaccharide (LPS).
Parasite survival N02
Experiment no., conditions rBPI23 (cpm ± SE) (nmol/well)
Experiment I
DMEM 53,646 ± 827 0.1
+ 55,066 ± 130 0.1
IFN-)'. 10 units/rnl, + 61,392 ± 2652 0.4
+ 57,426 ± 573 0.2
LPS, I ng/mL 374 ± 95 4.3
+ 58,953 ± 943 0.2
LPS, 3 ng/rnl, 498 ± 142 6.5
+ 57,060 ± 40 0.8
Experiment II
DMEM 39,222 ± 725 0
+ 42,940 ± 522 0
IFN-)', 100 units/mi. 36,988 ± 717 0
+ 42,623 ± 630 0
IFN-)', 10 units/rnl, + LPS, 70 ± 5 6.5
3ng/mL + 47,351 ± 992 0.2
IFN-)', 100 units/ml, + TNFa, 5456 ± 176 2.4
1000 units/ml, + 2647 ± 302 2.5
NOTE. Data are from 2 independent experiments and represent 5 ex-
periments. DMEM, Dulbecco's MEM; IFN-)', interferon-v; TNFa, tumor
necrosis factor-a. rBPI23 , I JLg/mL. Nitrite (N02), SE ..,;;;0.3 nrnol/well
(n = 3).
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efficiency of BPI in inhibiting the lethal consequences of en-
dotoxic shock should consider possible effects on NO produc-
tion, we first assessed the capacity of rBPI23 to inhibit N02"
release by macrophages stimulated in vitro by IFN-'Y plus
LPS or by IFN-'Y plus TNFQ'.
Preliminary studies on LPS-elicited TNF secretion by
bone marrow-derived macrophages demonstrated that
rBPI 23 inhibited release of this mediator at concentrations
equivalent to those previously reported by Marra et al. [20]
for human monocytes. In those studies, LPS was preincu-
bated with purified BPI. In our experiments, LPS was added
to cell cultures containing rBPI 23 and 1% NMP was immedi-
ately added. Using a similar protocol with IFN-'Y-primed
macrophages, we found that rBPI23 inhibited LPS-triggered
NO production with an approximate ICso of 0.1-0.3 ,ug/mL
(4-12 nM). These concentrations are nearly identical to
those reported by Ooi et al. [18] for the inhibition by an
Nl-lj-terminal BPI fragment ofTNF secretion in whole blood
elicited by I ng/rnl, LPS. Furthermore, on a molar basis,
rBPI23 was at least as effective as polymyxin B (data not
shown), in agreement with results of Marra et al. [20] on
effects of polymyxin B and soluble BPI on in vivo induction
of TNFQ' secretion. When we later examined the effect of
rBPI 23 on macrophage binding of FITC-LPS, half-maximal
inhibition was observed at concentrations similar to those
obtained for inhibition of NO production. These concentra-
tions are also similar to the reported Kd of rBPI 23 for various
LPS [21).
As shown in control experiments, N02" production elicited
by IFN-'Y plus TNFQ' is unaffected by rBPI23 , demonstrating
specificity for LPS-activated macrophages. Of note, under
the conditions used in these studies (i.e., low IFN-'Y and LPS
concentrations and assay of N02" at 24 h), TNF is not an
important cofactor for LPS-induced NO production. The
amount of bone marrow macrophage TNF secreted is much
less than the concentrations used here to trigger NO produc-
tion (these studies and [9]). Furthermore, antibody to mu-
rine TNFQ' did not inhibit N02" production by cultures stimu-
lated with IFN-'Y plus LPS [45].
Interestingly, rBPI 23 inhibited N02" production when
added several hours after LPS. Similar results were obtained
with polymyxin B or rabbit anti-O III LPS (not shown). Elic-
itation of NO production is a relatively slow process, with
N02" release first detectable 4-8 h after stimulation. Our re-
sults demonstrate that induction occurs more quickly at 10
ng/rnl. LPS than at a IO-fold lower concentration, suggesting
that low concentrations ofLPS stimulate certain macrophage
responses such as NO synthase activity by a slow accumula-
tion of multiple signal-transducing events. The ability of
rBPI 23 to inhibit NO production when added after LPS con-
trasts with our previous results on inhibition ofTNF produc-
tion by human monocytes [23). It remains to be seen
whether LPS recognition and signal-transduction events
leading to NO production and TNFQ' secretion are signifi-
cantly different. .
Alternatively, plasma or cellular components involved in
LPS-dependent macrophage activation may vary between
the human and murine systems. As shown here, antibody to
murine plasma LBP inhibited NO;- release, consistent with
our previous results using purified LBP [9). However, it is
also clear that NO production elicited by higher LPS concen-
trations can occur in the absence of plasma or plasma LBP.
Furthermore, rBPI 23 inhibits N02 release in the presence or
absence ofNMP, and thus ofLBP.
rBPI 23 also inhibited macrophage leishmanicidal activity
induced by IFN--y plus LPS but not by IFN-'Y plus TNFQ'.
These experiments underline the specificity ofrBPI23 for LPS
and provide a sensitive in vitro model to demonstrate lack of
toxicity for macrophages since control unstimulated cells
support an intracellular microbial infection equally well in
the presence or absence of rBPI 23 .
Taken together, these results suggest that rBPI23 might be
an effective inhibitor of NO production in vivo where con-
centrations of LPS rarely exceed picogram per milliliter lev-
els [46, 47). Moreover, inhibition of LPS-elicited TNF pro-
duction by rBPI 23 could provide a further level of control of
inducible NO synthase activity in gram-negative shock. The
relative role of this pathway in patients or in murine models
of endotoxemia remains a controversial issue that deserves
further study.
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